1. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial. Issue 10358 (1st October 2022) Authors: Livingstone, Elisabeth; Zimmer, Lisa; Hassel, Jessica C; Fluck, Michael; Eigentler, Thomas K; Loquai, Carmen; Haferkamp, Sebastian; Gutzmer, Ralf; Meier, Friedegund; Mohr, Peter; Hauschild, Axel; Schilling, Bastian; Menzer, Christian; Kiecker, Felix; Dippel, Edgar; Roesch, Alexander; Ziemer, Mirj... Journal: Lancet Issue: Volume 400:Issue 10358(2022) Page Start: 1117 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. Issue 10236 (16th May 2020) Authors: Zimmer, Lisa; Livingstone, Elisabeth; Hassel, Jessica C; Fluck, Michael; Eigentler, Thomas; Loquai, Carmen; Haferkamp, Sebastian; Gutzmer, Ralf; Meier, Friedegund; Mohr, Peter; Hauschild, Axel; Schilling, Bastian; Menzer, Christian; Kieker, Felix; Dippel, Edgar; Rösch, Alexander; Simon, Jan-Chris... Journal: Lancet Issue: Volume 395:Issue 10236(2020) Page Start: 1558 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns—Results of a non-interventional study of the DeCOG. (June 2018) Authors: Hillen, Uwe; Leiter, Ulrike; Haase, Sylvie; Kaufmann, Roland; Becker, Jürgen; Gutzmer, Ralf; Terheyden, Patrick; Krause-Bergmann, Albrecht; Schulze, Hans-Joachim; Hassel, Jessica; Lahner, Nina; Wollina, Uwe; Ziller, Fabian; Utikal, Jochen; Hafner, Christine; Ulrich, Jens; Machens, Hans-Günther; W... Journal: European journal of cancer Issue: Volume 96(2018) Page Start: 34 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV600 mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial. (November 2021) Authors: Zimmer, Lisa; Livingstone, Elisabeth; Krackhardt, Angela; Schultz, Erwin S.; Göppner, Daniela; Assaf, Chalid; Trebing, Dietrich; Stelter, Kai; Windemuth-Kieselbach, Christine; Ugurel, Selma; Schadendorf, Dirk Journal: European journal of cancer Issue: Volume 158(2021) Page Start: 72 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗